首页> 外文期刊>Oncology reports >microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer
【24h】

microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer

机译:microRNA-520a-3p通过靶向非小细胞肺癌中的HOXD8抑制增殖和癌症干细胞表型

获取原文
获取原文并翻译 | 示例
           

摘要

Formation of cancer stem cells (CSCs) and increased cells proliferation are involved in tumorigenesis, tumour recurrence and therapy resistance and microRNA is essential for the development of the biological traits of CSCs and the increased cells proliferation. Studying molecular mechanism of tumorigenesis, tumour recurrence and therapy resistance of lung cancer will help us to further understand the pathogenesis and progression of the disease and offer new targets for effective therapies. In the present study, we found that miR-520a-3p expression is downregulated in NSCLC (non-small cell lung cancer) and SCLC (small cell lung cancer). miR-520a-3p can inhibit proliferation and cancer stem cell phenotype in NSCLC and SCLC cells. Overexpressing miR-520a-3p can degrade HOXD8 mRNA in NSCLC cells, but its overexpression cannot suppress HOXD8 in SCLC cells. HOXD8 protein is upregulated in NSCLC tissues and its overexpression can promote proliferation, formation of cancer stem cells, migration and invasion in NSCLC cells. MET amplification plays a pivotal role in gefitinib resistance in lung cancer. We found that miR-520a-3p can downregulate MET protein expression and HOXD8 can upregulate MET protein expression. Thus, we concluded that microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in NSCLC cells and restoration of microRNA-520a-3p might be a therapeutic strategy to reverse gefitinib resistance.
机译:肿瘤干细胞(CSCs)的形成和细胞增殖的增加与肿瘤的发生,肿瘤的复发和治疗耐药有关,microRNA对于CSCs生物学特性的发展和细胞增殖的增加至关重要。研究肺癌的发生,发展,复发和治疗耐药性的分子机制将有助于我们进一步了解该疾病的发病机理和进展,并为有效治疗提供新的靶点。在本研究中,我们发现miR-520a-3p表达在NSCLC(非小细胞肺癌)和SCLC(小细胞肺癌)中被下调。 miR-520a-3p可以抑制NSCLC和SCLC细胞的增殖和癌干细胞表型。过度表达的miR-520a-3p可以降解NSCLC细胞中的HOXD8 mRNA,但其过度表达不能抑制SCLC细胞中的HOXD8。 HOXD8蛋白在NSCLC组织中上调,其过表达可促进NSCLC细胞的增殖,癌症干细胞的形成,迁移和侵袭。 MET扩增在肺癌的吉非替尼耐药中起关键作用。我们发现miR-520a-3p可以下调MET蛋白表达,而HOXD8可以上调MET蛋白表达。因此,我们得出的结论是,microRNA-520a-3p通过靶向NSCLC细胞中的HOXD8抑制增殖和癌症干细胞表型,并且恢复microRNA-520a-3p可能是逆转吉非替尼耐药性的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号